PRMT5 and non-small cell lung carcinoma: PF-06939999, a selective SAM-competitive PRMT5 inhibitor, showed anti-proliferative activity in non-small cell lung cancer (NSCLC) cell models, primarily impacting the pathways responsible for regulating the cell cycle and alternative splicing.